Open Orphan article published in Drug Discovery Today

Open Orphan

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced an article submission has been published in Drug Discovery Today, a print and online trade magazine with an emphasis on the science which underpins drug discovery and development. The published editorial is titled “Modelling the World – can deliberately infecting healthy volunteers really tell us much about what happens outside the clinic during an epidemic or pandemic?”

The article was written by Adrian Wildfire, Director of Scientific and Business Strategy at hVIVO, part of Open Orphan plc. Adrian is a specialist in the fields of virology, medical microbiology and parasitology.

The article explores what can be learned from using the method of human challenge trials to support vaccine development, and focuses on the role hVIVO plays in this, in particular in relation to COVID-19. hVIVO has a long history of successfully delivering human challenge studies at their state-of-the-art quarantine facility in East London.

CEO Cathal Friel told DirectorsTalk,

“This surrounds an interesting research article which was published in recent days in Drug Discovery Today, a well-respected scientific journal publication. The article was authored by Adrian Wildfire hVIVO’s Director of Scientific & Business Strategy, it makes very interesting reading and proves the value that for some disease indications, the human challenge study model is the only way to test efficacy of some infectious disease therapeutics especially during a period of a pandemic.”

To view the article, please follow the link:

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, hVIVO welcomes volunteers under expertly supervised conditions, to further medical research, and help us to take the understanding of respiratory illnesses to a new level. Volunteers are central to the work that we do; our studies focus on testing new treatments on real people, in a safe, controlled, clinical environment.

Further details on all aspects of our volunteer programs including testimonials from previous volunteers can be found at

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at

You might also enjoy reading  Open Orphan's hVIVO wins a £7.3m influenza human challenge study
Find more news, interviews, share price & company profile here for:
Open Orphan plc

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit
Find more news, interviews, share price & company profile here for:
Open Orphan plc

AIM All Share Index